HC Wainwright reaffirmed their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $14.00 target price on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings […]
HC Wainwright reiterated their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $14.00 target price on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, […]
PolyPid (NASDAQ:PYPD – Get Free Report) and LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings. Earnings and Valuation This table compares PolyPid and […]
PolyPid (NASDAQ:PYPD – Get Free Report) and Assure (NASDAQ:IONM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings. Risk and Volatility PolyPid has a beta of 1.45, […]
PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the recipient of a significant decline in short interest in November. As of November 15th, there was short interest totalling 1,000 shares, a decline of 68.8% from the October 31st total of 3,200 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average […]